Clinical trials
HER2 Positive Solid Tumor clinical trials
Below are recruiting her2 positive solid tumor clinical trials, each written for real people, not researchers. We’re tracking 158 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06526819RecruitingPhase 1/Phase 2
New drug SMP-3124LP for advanced solid tumors
This trial tests a new drug called SMP-3124LP for people with advanced solid tumors that no longer respond to standard treatments. It is given in two phases: first to find the best dose (dose escalation) and then to see how well it works in specific cancer types (dose expansion).
Los Angeles, CaliforniaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT05866692RecruitingPhase 1
First-in-human capsule for advanced solid tumors
This Phase 1 study tests a new oral capsule (TY-2699a) in people with advanced or metastatic solid tumors that have limited treatment options. It will look for the safest dose and whether the drug can shrink tumors, especially in certain genetic/biomarker patterns.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT05245058RecruitingEarly Phase 1
SPH5030 for HER2-positive advanced solid tumors
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Hefei, AnhuiAges 18 years+ - NCT06208410RecruitingPhase 1/Phase 2
JS105 plus other treatments for advanced solid tumors
This trial tests a new drug called JS105 combined with other anti-cancer therapies for people with certain advanced breast, ovarian, endometrial, or cervical cancers. It aims to find out if these combinations are safe and effective.
Zhengzhou, HenanAges 18–75 - NCT06806982RecruitingPhase 1
Study of VRN101099 for HER2-positive solid tumors
This trial tests a new drug, VRN101099, for people with HER2-positive or HER2-mutated cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow cancer growth.
Darlinghurst, New South WalesAges 18 years+ - NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06669975RecruitingPhase 1/Phase 2
Testing AP402 for her2-positive advanced solid tumors
This trial tests an experimental drug called AP402 for people with HER2-positive solid tumors that have spread or cannot be removed by surgery, and who have no standard treatment options left. The goal is to see if AP402 can shrink tumors or slow their growth.
Macquarie, New South WalesAges 18 years+ - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05957536RecruitingPhase 1
Testing a new drug for HER2-positive advanced solid cancers
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
Stanford, CaliforniaAges 18 years+ - NCT07258121RecruitingPhase 1/Phase 2
ZGGS34 for Advanced Solid Tumors Targeting MUC17
This trial tests an experimental drug called ZGGS34 that targets a protein (MUC17) found on some cancer cells. It is designed for people with advanced solid tumors (stomach, pancreas, colorectal, or other) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–75 - NCT07192432RecruitingPhase 1/Phase 2
Gene therapy for HER2-positive cancer
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Los Angeles, CaliforniaAges 18 years+ - NCT07009184RecruitingEarly Phase 1
Imaging study for HER2-positive cancers using TGW211
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
Nijmegen, GelderlandAges 18 years+ - NCT06015048RecruitingPhase 1/Phase 2
SHR-A1811 plus other therapies for advanced HER2+ tumors
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Hefei, AnhuiAges 18–75 - NCT05631964RecruitingPhase 1
Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT05423977Enrolling by invitationPhase 1
Testing ZV0203 for HER2-positive advanced solid tumors
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Zigong, ShandongAges 18 years+ - NCT05940896RecruitingPhase 1
HER2-targeted drug with radiation for non-surgical solid cancers
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
Jinan, ShandongAges 18 years+ - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70
Hear when a new HER2 Positive Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive solid tumor?
- Yes. Clin2 currently lists 158 recruiting her2 positive solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.